Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to “Buy” at Jefferies Financial Group
Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) from a hold rating to a buy rating in a research report sent to investors on Monday, Marketbeat reports.
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), citing the company’s robust cystic fibrosis base business ...
TD Cowen Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s ...
Vertex reports positive long-term data for Casgevy
Vertex Pharmaceuticals (VRTX) presented positive long-term data for its gene therapy Casgevy and issued a business update on ...
The Pharma Letter2d
Vertex’ suzetrigine deemed ‘slightly cost-saving’
US biopharma Vertex Pharmaceuticals has previously presented positive Phase III data on suzetrigine, an investigational, oral ...
2 No-Brainer Stocks to Buy Before the End of 2024
I think the stock market's valuation has become frothy. And I'm in good company; Warren Buffett's actions show that he shares ...
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $469.29, indicating a -0.99% shift from the previous trading day.
Business Wire4d
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive ...
Vertex, bluebird join new federal program to pay for gene therapies
Vertex Pharmaceuticals Inc. and bluebird bio Inc. — are the first to take part in a new Medicaid model intended to expand ...